Roularta Media Group

BELGIUM Bloomberg: ROU:BB Reuters: RLRT.BR



1H19 results: key highlights

Roularta reported a strong set of interim results, reflecting improved gross margins and, more importantly, strong cost control with an efficient integration of the recent acquisition of the women magazine titles from Sanoma. Organic sales declined by 6.3% driven mainly by weak advertising sales, while Printing sales held up well reflecting strong capacity utilisation. Roularta performed much stronger than expected at the EBITDA level, mainly thanks to higher-than-expected gross margins and strong cost control (Opex ex-COGS at 72% of sales vs MERe 75.5%). EPS was stronger-thanexpected also driven by a lower-than-expected minority charge probably reflecting a lower loss contribution from Storesquare. Guidance remains qualitative with management highlighting the ongoing lack of visibility in advertising sales and the strong performance in Printing. Net debt is in line with our FY forecast. An analyst meeting is scheduled today at 1PM CET.

Merodis

Equity Research

€m	2015	2016	2017	2018	2019e	2020e	2021e
Sales	291.9	278.6	258.3	278.4	301.9	296.7	292.5
EBIT	12.3	6.7	-13.0	-63.7	-1.8	5.7	6.2
Net profit	64.4	21.5	-10.9	79.9	4.1	11.1	11.2
EPS (€)	4.92	1.65	-0.84	6.14	0.32	0.85	0.86
DPS (€)	0.50	0.50	0.00	5.50	0.50	0.50	0.55
P/E (x)	3.2	14.7	na	3.2	41.3	15.4	15.3
Yield (%)	3.2	2.1	0.0	28.0	3.8	3.8	4.2
Adj. EV/EBIT (x)	9.6	32.7	na	na	na	3.6	1.9

Quick ReAction – 1H19 results review

14 August 2019

1	1	H19 results		_	2019e	Marriella Frankla Danasark			
	Actuals		% A vs MER	MER est.		Merodis Equity Research comments			
Consolidated sales	147.9	150.9	-2.0	301.9	301.6	0.1 Sales growth was driven mainly by the Sanoma women magazine			
% growth	17.8	20.2		8.4	8.3	acquisition. Organic sales fell by 6.3% due to ongoing weakness in advertising revenues, particularly in the free sheet market (-12.8%). The numbers suggest sales from acquired titles (€14.4m) broadly in line with our forecasts (€15m). Media Brands sales were 2% below our forecast, while Printing sales were in line with our expectations.			
Adj. EBITDA	8.5	2.3	262.3	10.3	17.0	-39.8 Roularta performed much stronger than expected at the EBITDA			
% growth	na	na		25.6	108.5	level, mainly thanks to higher-than-expected gross margins (78% vs			
% sales	5.7	1.5		3.4	5.6	MERe 77.7%, up from 77.3% in 1H18) and strong cost control (Opex ex-COGS was 7% below our forecast and at 72% of sales vs MERe 75.5%).			
Adj. REBIT	1.7	-3.7	na	-1.8		Without any impairement (vs €63.2m taken in 1H18) and with			
% growth	na	na		na		depreciation and provisions slightly higher than we expected			
% sales	1.1	-2.4		-0.6		(€6.8m vs MERe €6m), the REBIT beat is also significant. Roularta is reporting its first positive REBIT since 2016, confirming a structural turnaround driven by the strategic review and focus on its core			
Reported EBIT*	3.9	-1.5	na	2.6	1.49	The reported EBIT includes equity accounted results as well as			
% growth	na	na		na	na	(limited) capitalised costs. Equity-accounted results reached €1.1m,			
% sales	2.6	-1.0		0.9	0.5	which is below our forecast of €2.2m.			
EPS	0.31	-0.04	na	0.32		-63.0 EPS was stronger-than-expected thanks to the above-mentioned			
% growth	-94.5	na		-94.8	-85.8	items as well as a lower-than-expected minority charge (€0.3m vs MERe €0.6m, probably reflecting a lower loss contribution from Storesquare), although net financial expenses (€0.04m) were slightly higher than we expected (net financial income of €0.4m). FY guidance remains qualitative with management highlighting the ongoing lack of visibility in terms of advertising sales (2H19 weakness should be in line with 1H19) and the strong performance in Printing (high capacity utilisation, confirmed by the recent investment in a new printing press).			
Net debt	-85.3			-81.1	-48.1	68.6 Net cash of €85m is broadly in line with our forecast of €81m for			
ND/EBITDA				-7.9	-2.8	end-December 2019, so no big surprise there.			

Source: Company data, Merodis Equity Research, Factset consensus (* Reported EBIT includes equity accounted results)

Arnaud W. Goossens ago@merodis.com

Source: Merodis Equity Research, Factset Pricing date: 13/08/2019



Disclaimer

This Report is solely for the information of the recipients. All information contained in this research report has been compiled from sources believed to be reliable. However, no representation or warranty, express or implied, is made with respect to the completeness or accuracy of its contents, and it is not to be relied upon as such. Opinions contained in this research report represent the authors' current opinions on the date of the report only. Merodis is not soliciting an action based upon it, and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of any offer to buy.

This report is provided solely for the information of professional investors who are expected to make their own investment decisions without undue reliance on this report and Merodis accepts no liability whatsoever for any direct or consequential loss arising from any use of this report or its contents.

ANALYST CERTIFICATION:

Merodis has been mandated by the subject company to produce a neutral, fair, and elaborate equity research report about the subject company with the aim to increase investors' awareness about the stock. The authors hereby declare that this report represents their personal opinion and that the company has neither limited nor in any other way influenced the content of this report. No part of the research analyst's compensation was, is, or will be, directly or indirectly, related to the specific opinions or views expressed by the research analyst in this research report.

The authors also declare that they are not shareholders of the subject company and that they have no other economic interest in the subject company than through their current mandate.

This Report is and at all times shall remain the exclusive property of Merodis.

This Report contains statements, estimates and projections provided by the Client concerning anticipated future performance. Such statements, estimates and projections reflect assumptions by our Client concerning anticipated results, which may or may not prove to be correct. No representations, expressed or implied are made as to the accuracy of such statements, estimates and projections.

All communication regarding this Report and requests for additional information should be directed to Merodis:

Arnaud W. Goossens Partner ago@merodis.com

For more information about

Merodis

please visit: www.merodis.com

